Abstract:B ackground: No consensus has been reached on the relationship between kit mutation and prognosis in core banding factor acute myeloid leukemia(CBF-AML). Our preverious analysis of kit mutation subtypes in patients with RUNX1-RUNX1T1 suggested poor prognosis associated with D816/D820 mutation. Objective: To investigate further risk stratification according to different subtypes of kit mutations and minimal residual disease (MRD) in CBF-AML. Methods: A total of 205 patients aged 16-70 years old with CBF-AML, who were diagnosed in our hospital, were analyzed retrospectively from January 2014 to April 2019. The effects of kit mutation subtypes and MRD on the overall survival (OS) and relapse free survival(RFS) were analyzed. Results: Of all, 118 males and 87 females were included. The median age were 38 (15-70) years old. Patients with RUNX1-RUNX1T1 and patients with CBFB-MYH11 accounted for 71.1% (147/205) and 28.3% (58/205) respectively. The ratio of kit mutation was 33.2% (68/205), of which, 52/147(35.4%) patients were RUNX1-RUNX1T1 positive, and 16/58 (27.6%) patients were CBFB-MYH11 positive. Of 68 patients with kit mutation, patients with D816/D820 mutation accounted for 50.0%(34/68) and the rest 34 cases were non D816/D820 mutation. The rate of D816/D820 mutation was 50% (26/52) and 50% (8/16) respectively in Patients with RUNX1-RUNX1T1 and patients with CBFB-MYH11. During the median follow-up time 28 (7-72) months, 10 patients were lost and a total of 195 patients were available. 42.6% (83/195) patients received allogeneic hematopoietic stem cell transplantation (allo-HSCT). 112 patients who did not received allo-HSCT were divided into three group: 85 patients without kit mutation(group A) , 15 patients with D816/D820 nutation(group B), 12 patients with non-D816/D820 nutation(group C). The 3-year overall survival(OS) and 3-year relapse free survival(RFS) between group A and B did not have significance(P=0.603, 0.601). Both the 3-year OS and 3-year RFS of group B were superior to group C(65.5% VS 8.3%; 73.3% VS 14.4%, P=0.002, 0.003), and the 3-year OS and 3-year RFS of group A were superior to group C(68.1% VS 8.3%; 75.2% VS 14.4%, P=0.000; 0.000). So group A and B were defined as low risk group (97 patients), group C defined as high risk group(15 patients). The 3-year OS and 3-year RFS of high risk group were significantly lower than those of low risk group(14.4% VS 75.4%、8.3% VS 68.4%, P=0.000、0.000). After 2 cycles of consolidation, MRD (the transcript of RUNX1-RUNX1T1 or CBFB-MYH11) > 0.1% could predicted disease recurrence(P=0.000). Patients who got MRD < 0.1%(49 patients) after two cycles of consolidation chemotherapy could have higher 3-year OS and 3-year RFS than those who did not (63 patients) (94.1%VS 49.9%; 96.3% VS 36.4%, P=0.000; 0.000). During the follow-up time, patients who achieved MRD < 0.1%(81patients) also had higher 3-year OS and 3-year RFS than those did not(31 patients)(81.8% VS 6.7%; 75.7% VS 12.9%, P=0.000, 0.000). Multivariate analysis showed D816/D820mutation, MRD > 0.1% after two cycles of consolidation chemotherapy, MRD > 0.1% during the follow-up time were poor prognosis on OS and RFS, and kit mutation had not effect on OS and RFS. A total of 91 patients out of 195 patients had D816/D820 mutation (30 patients) or MRD > 0.1% after two cycles of consolidation chemotherapy and MRD > 0.1% (61 patients) during the follow-up time, the 3-year OS and 3-year RFS significantly increased in the group of 57 patients who received allo-HSCT than the group of 34 patients who did not(91.0% VS 22.1%; 91.2% VS 15.9%, P=0.000, 0.000). Conclusion: The real high risk patients must be recognized during the treatment of CBF-AML: D816/D820mutation, MRD > 0.1% after two cycles of consolidation chemotherapy and MRD > 0.1% during the follow-up time. Allo-HSCT can improve the survival of patients who were distinguished under the accurate stratification. Disclosures No relevant conflicts of interest to declare.

The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia

The Clinical Impact of IKZF1 Mutation in Acute Myeloid Leukemia

A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia Patients

[Impact of KIT D816 Mutation on Salvage Therapy in Relapsed Acute Myeloid Leukemia with T(8;21) Translocation].

C-Kit-Mutated T(8;21) Aml Patients with > 3log Reduction of Mrd Conferred A Very High Relapse and Need Hsct to Improve Outcome

Combination of KIT and FLT3‐ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission

Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia

Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center

Role of CD19 and Specific KIT‐D816 on Risk Stratification Refinement in T(8;21) Acute Myeloid Leukemia Induced with Different Cytarabine Intensities

Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation

Risk-Stratification Treatment Directed By Minimal Residual Disease Improves The Outcome Of Acute Myeloid Leukemia With T(8;21) In First Complete Remission: Results Of The Aml05 Multicentre Trial

Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: A comprehensive large-scale study from a single Chinese center

Co-occurrence of KIT and NRAS mutations defines an adverse prognostic core-binding factor acute myeloid leukemia

Kit Mutation Versus Mrd, Which is More Important to Predict Relapse of Acute Myeloid Leukemia with T (8;21)?

Both the Subtypes of Kit Mutation and Minimal Residual Disease Are Associated with Prognosis in Core Banding Factor Acute Myeloid Leukemia

In Adults with T(8;21)aml, Posttransplant RUNX1/RUNX1T1-based MRD Monitoring, Rather Than C-Kit Mutations, Allows Further Risk Stratification.

The Quantification of Minimal Residual Disease Pre‐ and Post‐Unmanipulated Haploidentical Allograft by Multiparameter Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia

Impact of pretransplantation risk factors on post transplantation outcome of patients with acute myeloid leukemia in remission after haploidentical hematopoietic stem cell transplantation.

The Impact of CD19 Expression Combined with Measurable Residual Disease on Post-Remission Treatment and Outcome in Adult t(8;21) Acute Myeloid Leukemia

The Impact of Minimal Residual Disease Prior to Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia in Complete Remission